This move is archived. Current quotes and coverage live on the stock page.
Get HBP alerts:
Helix BioPharma Corp. is facing a downturn as its stock slips 0.67% in the latest trading session.
In the last trading session, Helix BioPharma Corp. (HBP.TO) saw its stock price decline by 0.67%, closing at CA$1.49. This drop reflects ongoing challenges in the biotech sector, especially for small-cap companies like Helix, which are dealing with pressures in the capital markets.
Investor takeaway: Investors should be cautious as Helix BioPharma navigates a tough financial landscape, marked by a lack of recent positive news and ongoing fundraising efforts.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$137.48M
52W high
$5.40
52W low
$1.10
1W change
-6.74%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 38.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+38.9% Upside
Current Price
C$1.80
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
67.8%
Annualized
90-Day Vol
65.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.15
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.91 | C$1.51 โ C$2.41 |
| 60 trading days | C$2.03 | C$1.46 โ C$2.82 |
| 90 trading days | C$2.15 | C$1.44 โ C$3.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Market Cap at CA$114.57 Million
Despite a market cap of CA$114.57 million, Helix's stock performance shows investor uncertainty in a challenging financial environment.
Bull case
If Helix manages to secure the necessary capital and advance its therapeutic programs, it could improve investor sentiment and boost its stock performance.
Bear case
On the other hand, if Helix continues to struggle with funding and doesnโt deliver significant positive news, its stock price could drop further, raising concerns about its long-term viability.
Current Market Performance
Advertisement
Helix BioPharma Corp. closed down 0.67% in the latest trading session, reflecting investor concerns about the company's financial health and future prospects. With a market cap of CA$114.57 million, the stock's recent performance highlights the volatility often seen in the biotech sector.
Challenges Ahead
The company has been clear about its need for capital to support ongoing operations and development. Recent announcements about fundraising efforts emphasize the pressure Helix is under to secure financing in a tough market. Without significant positive news, investor confidence may continue to decline.
Looking Forward
As Helix BioPharma works to stabilize its financial footing, investors should keep a close eye on developments. The company's ability to attract institutional investment and advance its therapeutic programs will be crucial in determining its future stock performance. For more insights, visit Helix BioPharma Corp. stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
